Abstract
Human C2orf69 is an evolutionary-conserved gene whose function is unknown. Here, we report 9 children from 5 unrelated families with a fatal syndrome consisting of severe auto-inflammation, progredient leukoencephalopathy with recurrent seizures that segregate homozygous loss-of-function C2orf69 variants. C2ORF69 orthologues, which can be found in most eukaryotic genomes including that of unicellular phytoplanktons, bear homology to esterase enzymes. We find that human C2ORF69 is loosely bound to the mitochondrion and its depletion affects mitochondrial membrane potential in human fibroblasts and neurons. Moreover, we show that CRISPR/Cas9-inactivation of zebrafish C2orf69 results in lethality by 8 months of age due to spontaneous epileptic seizures which is accompanied by persistent brain inflammation. Collectively, our results delineate a novel auto-inflammatory Mendelian disorder of C2orf69 deficiency that disrupts the development/homeostasis of the immune and central nervous systems as demonstrated in patients and in a zebrafish model of the disease.
One Sentence Summary C2orf69 is a putative enzyme whose inactivation in humans and zebrafish causes a hitherto unknown auto-inflammatory syndrome.
Competing Interest Statement
J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics (BG) Laboratories. JRL serves on the Scientific Advisory Board of BG. A.B.A. and P.B. are employees of CENTOGENE GmbH. Other authors have no potential conflicts to report.
Funding Statement
H.H.W. and S.H.S are supported by a grant from Procter & Gamble (P&G). The Laboratory of Human Genetics of Infectious Diseases is supported by the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR001866), the French National Research Agency (ANR) under the Investments for the Future ANR program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the PNEUMOPID project (Grant ANR 14-CE15-0009-01), the French Foundation for Medical Research (FRM) (EQU201903007798), the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Sante et de la Recherche Medicale (INSERM), and the Universite de Paris. S.X. is supported by NMRC/OFYIRG/062/2017. A.S.M. and F.M.N. were supported by the Ministry of Education, Singapore and Yale-NUS College (grant numbers IG18-SG103, and SUG). LH is supported by fellowships NRF-NRFF2017-05 (National Research Foundation of Singapore) and HHMI-IRSP55008732 (Howard Hughes Medical Institute International Research Scholar Program). T.M. is supported by the Uehara Memorial Foundation. D.P. is supported by International Rett Syndrome Foundation (IRSF grant #3701-1). J.R.L. is supported by the U.S. National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (UM1 HG006542). B.R. is an investigator of the National Research Foundation (NRF, Singapore), Branco Weiss Foundation (Switzerland) and an EMBO Young Investigator, and is supported by an inaugural Use-Inspired Basic Research (UIBR) central fund from the Agency for Science & Technology and Research (A*STAR) in Singapore.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was provided according to the Baylor-Hopkins Center for Mendelian Genomics Research Protocol (IRB number: H-29697). All human studies were reviewed and approved by the the Rockefeller University Hospital (New York, USA) and the institutional review boards of A *STAR (2019-087).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author B.R. The data are not publicly available due to restrictions to ensure privacy of research participants.
